NasdaqGM - Delayed Quote USD

Cara Therapeutics, Inc. (CARA)

0.6719 +0.0007 (+0.10%)
At close: 4:00 PM EDT
0.6719 0.00 (0.00%)
After hours: 4:41 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
16,938.0000
20,968.0000
41,867.0000
23,028.0000
135,082.0000
--
Cost of Revenue
4,204.0000
6,174.0000
7,266.0000
--
--
--
Gross Profit
12,734.0000
14,794.0000
34,601.0000
23,028.0000
135,082.0000
--
Operating Expense
133,844.0000
136,289.0000
122,136.0000
112,111.0000
129,697.0000
--
Operating Income
-121,110.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
--
Net Non Operating Interest Income Expense
-2,586.0000
-604.0000
--
--
--
--
Other Income Expense
1,152.0000
3,586.0000
2,061.0000
642.0000
2,334.0000
--
Pretax Income
-122,544.0000
-118,513.0000
-85,474.0000
-88,441.0000
7,719.0000
--
Tax Provision
--
--
--
--
-691.0000
-816.0000
Net Income Common Stockholders
-122,544.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
--
Diluted NI Available to Com Stockholders
-122,544.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
--
Basic EPS
-2.26
-2.19
-1.59
-1.74
0.18
--
Diluted EPS
-2.26
-2.19
-1.59
-1.74
0.18
--
Basic Average Shares
54,328.0720
54,149.0590
53,653.5640
50,718.7650
47,413.2500
--
Diluted Average Shares
54,328.0720
54,149.0590
53,653.5640
50,718.7650
47,915.0300
--
Total Operating Income as Reported
-123,511.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
--
Total Expenses
138,048.0000
142,463.0000
129,402.0000
112,111.0000
129,697.0000
--
Net Income from Continuing & Discontinued Operation
-122,544.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
--
Normalized Income
-120,143.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
--
Interest Expense
2,586.0000
604.0000
--
--
--
--
Net Interest Income
-2,586.0000
-604.0000
--
--
--
--
EBIT
-119,958.0000
-117,909.0000
-85,474.0000
-88,441.0000
5,385.0000
--
EBITDA
-119,715.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
--
Reconciled Cost of Revenue
4,092.0000
6,045.0000
7,146.0000
--
--
--
Reconciled Depreciation
243.0000
259.0000
248.0000
248.0000
209.0000
--
Net Income from Continuing Operation Net Minority Interest
-122,544.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
--
Total Unusual Items Excluding Goodwill
-2,401.0000
--
--
--
--
--
Total Unusual Items
-2,401.0000
--
--
--
--
--
Normalized EBITDA
-117,314.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
--
Tax Rate for Calcs
--
--
--
--
0.0003
--
12/31/2019 - 1/31/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GOSS Gossamer Bio, Inc.
0.5945
-4.10%
 
KPTI Karyopharm Therapeutics Inc.
0.9935
-5.38%
 
NKTR Nektar Therapeutics
1.5000
-8.54%
 
KOD Kodiak Sciences Inc.
3.0000
-2.28%
 
SGMO Sangamo Therapeutics, Inc.
0.6213
+4.39%
 
UNCY Unicycive Therapeutics, Inc.
0.8356
-11.66%
 
KZR Kezar Life Sciences, Inc.
0.7120
+0.99%
 
ABEO Abeona Therapeutics Inc.
4.1000
+0.99%
 
ATRA Atara Biotherapeutics, Inc.
0.6115
-2.00%
 
CLDI Calidi Biotherapeutics, Inc.
0.2591
+13.24%